29 published test results across 11 vendors · latest: 25 Nov 2025
| # | Vendor | Tests | Price/mg | Score |
|---|---|---|---|---|
| 1 | PPlanet Peptide Unverified | 3 | $8.00 | 70 |
| 2 | PPolaris Peptides | 3 | $15.00 | 70 |
| 3 | TTydes Unverified | 3 | $17.50 | 70 |
| 4 | UUther Unverified | 2 | — | 68 |
| 5 | PPeptide-S Unverified | 4 | $1.80 | 65 |
| 6 | LLN Peptides Unverified | 1 | — | 65 |
| 7 | SSkye Peptides | 5 | $16.50 | 62 |
| 8 | BBulk Peptide Supply | 1 | — | 57 |
| 9 | NNuscience Peptides | 2 | $20.90 | 54 |
| 10 | PPharma Grade Peptides | 2 | $20.00 | 54 |
Computed from publicly published third-party results. How scoring works · every listing is free and un-buyable. Vendors marked Unverified appear for their published results but are left out of the vendor rankings.
Mazdutide is a GLP-1 and glucagon dual agonist from Innovent and Eli Lilly that made history in June 2025 as the first drug of its class approved anywhere, clearing China’s NMPA for weight management, with a type 2 diabetes approval following that September. Its GLORY-2 trial reported up to 20.1% weight loss at the 9 mg dose.
Here is the oddity in the data: mazdutide’s entire top three last published tests in May 2025, the month before its Chinese approval, and the rest of the board stopped at October 2025. Twenty-eight tests across ten vendors, and essentially nothing since. The likely reading is that approval in China redirected both supply and attention, leaving the research-chemical record to fossilize. Whatever the cause, every score on this board describes batches from over a year ago, which makes batch-level verification non-negotiable for anyone buying today.
Scores of 68 to 73 on records of one to three tests each, at published prices from $8.00 to $17.50 per milligram, which is steep against the dual-agonist competition. Thin records, high prices, and frozen dates: if a vendor offers mazdutide now, ask for a 2026 certificate before anything else, and verify it against the issuing lab.
No. The NMPA approvals in 2025 were world-firsts for the class, and no US or European approval exists. Research-market vials sold elsewhere are unregulated product.
The published record does not say, only that it stopped. Approval-driven supply shifts are the plausible explanation. Practically, it means no current score on this board should be trusted without a fresh batch certificate.
Different receptor pairings and different trial profiles, covered on the tirzepatide and retatrutide pages. In the gray market the practical difference is data: those two have thousands of fresh published tests, mazdutide has twenty-eight old ones.
Nothing on this page is medical advice; compounds shown are sold for research purposes only. Data is aggregated from publicly published third-party results and traces to its source.